Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;79(5):573-578.
doi: 10.1007/s40265-019-01076-2.

Toripalimab: First Global Approval

Susan J Keam  1
Affiliations
Review

Toripalimab: First Global Approval

Susan J Keam. Drugs. 2019 Apr.

Abstract

Toripalimab, a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2), is being developed by Shanghai Junshi Bioscience Co., Ltd in China for the treatment of various cancers. In December 2018, based on positive efficacy results of a phase 2 trial and safety data from several clinical studies, toripalimab received conditional approval in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy. This article summarizes the milestones in the development of toripalimab leading to this first global approval for the treatment of unresectable or metastatic melanoma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eur J Cancer. 2012 Jan;48(1):94-100 - PubMed
    1. Acta Pharmacol Sin. 2017 May;38(5):710-718 - PubMed
    1. J Hematol Oncol. 2019 Jan 14;12(1):7 - PubMed
    1. J Clin Oncol. 2019 Nov 10;37(32):2987-2999 - PubMed

MeSH terms